Colorectal Cancer Trial, Recruiting NCT06620627 Sponsor: Natera, Inc. Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT06620627
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 40 years of age or older at the time of signing the consent form
  • People who are planning to have a colonoscopy as a routine screening (not because of symptoms)
  • People who are able to have blood drawn through a needle for research purposes
  • People who are able and willing to provide blood samples within the 120 days before their colonoscopy
  • People who are willing and able to follow the study schedule and meet all study requirements
  • People who have signed the required consent forms before the study begins

Who may not be able to join:

  • People who have any personal history of cancer of any kind (an exception may apply for people who had certain non-melanoma skin cancers surgically removed at least 12 months before signing the consent form — confirm with trial site)
  • People who have had a full colonoscopy with adequate bowel preparation within the past 9 years
  • People who are having a colonoscopy to investigate symptoms such as unexplained long-lasting diarrhea or visible rectal bleeding (such as blood in the stool) within the past 30 days
  • People who have recently had a bowel cancer screening test within the intervals listed below:
    • A stool-based test (FOBT or FIT) within the past 12 months
    • A stool DNA test (FIT-DNA) within the past 36 months
    • A blood-based bowel cancer screening test within the past 36 months
    • A CT colonography scan within the past 5 years
    • A flexible sigmoidoscopy within the past 5 years
  • People whose most recent colonoscopy found pre-cancerous growths (note: benign or hyperplastic polyps do not count as exclusions — confirm with trial site)
  • People who have previously had part of their bowel surgically removed for any reason other than a condition called sigmoid diverticular disease
  • People who have been diagnosed with, or have a personal history of, any of the following conditions that carry a high risk of bowel cancer:
    • Inflammatory bowel disease (IBD), including ulcerative colitis or Crohn's disease
    • Familial adenomatous polyposis (FAP), including the less severe form called attenuated FAP
    • Lynch Syndrome (also called hereditary non-polyposis colorectal cancer or HNPCC)
    • Other inherited cancer syndromes, including but not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis, Gardner's Syndrome, Turcot's Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis, and Familial Hyperplastic Polyposis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 6504899050

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Natera, Inc.
Registry
ClinicalTrials.gov
Start date
26 January 2024
Est. completion
31 July 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Primary Objective

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov